COMPREHENSIVE OPTOMETRY SIMPLIFIED

HOW TO INCREASE MEDICAL MANAGEMENT, ADHERE TO PRACTICE GUIDELINES, AND DECREASE DEPENDENCE ON MANAGED VISION CARE

KYLE D KLUTE, OD, FAAO

GOOD LIFE EYECARE

OMAHA, NE & GLENWOOD, IA



www.EyeCodeEducation.com



WHAT ARE YOUR BIGGEST CHALLENGES, OBSTACLES, AND HEADACHES IN COMPREHENSIVE OPTOMETRY?

Too much dependence on managed vision care

Adhering to disease standards of care/guidelines

Billing and coding appropriately

Getting paid appropriately/remaining profitable

Integrating vision/refractive AND medical care

ALL OF THE ABOVE?



IS (SUB)SPECIALIZATION THE ANSWER?

MY PROBLEMS PROBLEMS (GRIEVANCES) WITH (SUB)SPECIALIZATION



Urban-centric – indirectly hurts rural optometry

Chronic eye disease are rarely isolated

The average eye care consumer does not care

Perpetuates a false dichotomy b/t medical and refractive eye care

It is not best for your patient



OPTOMETRISTS ARE THE BEST TRAINED BEST POSITIONED PRIMARY EYE CARE PROVIDERS. PERIOD.

WHAT IS PRIMARY EYE CARE?



"Primary eye care is the provision of appropriate, accessible, and affordable care that meets patients' eye care needs in a comprehensive and competent manner"

WHAT IS PRIMARY EYE CARE?

- Educating patients about maintaining and promoting healthy vision.
- Performing a comprehensive examination of the visual system.
- Screening for eye diseases and conditions affecting vision that may be asymptomatic.
- Recognizing ocular manifestations of systemic diseases and systemic effects of ocular medications.
- Making a differential diagnosis and definitive diagnosis for any detected abnormalities.
- Performing refractions.
- Fitting and prescribing optical aids, such as glasses and contact lenses.
- Deciding on a treatment plan and treating patients' eye care needs with appropriate therapies.
- Counseling and educating patients about their eye disease conditions.
- Recognizing and managing local and systemic effects of drug therapy.
- Determining when to triage patients for more specialized care and referring to specialists as needed and appropriate.
- Coordinating care with other physicians involved in the patient's overall medical management.
- Performing surgery when necessary.



WHAT IS THE REALITY?

- 30% of ODs do ZERO medical
- In 2019:
 - 62.7% of ODs billed Medicare in 2019
 - 32% of ODs billed Medicare for fundus photos
 - 29.5% of ODs billed Medicare for VF
 - 27% of ODs billed Medicare for OCTs

Optometry & Medical EyeCare 2016 to 2021 (CMS-FFS)



Figure used with permission from Richard Edlow, OD



"~15x growth in medical eye exams from 2020 to 2030 when comparing routine vision exams vs medical eye exams" – Richard Edlow, OD "Eyeconomist"

WHAT IS THE REALITY IN SOUTH DAKOTA?



	Average	High	Low	GOAL
992x3 vs. 992x4 Ratio	Ś	Ś	Ś	~ 1.00
992xx per Refraction	Ş	ş	Ş	> 50%
VF per Refraction	Ş	Ş	Ş	10%
		Ś		
OCT-N per Refraction	Ś		Ş	10%
Gonio per Refraction	Ś	Ś	Ś	10%
OCT-M per Refraction	Ś	Ś	Ś	10%
Fundus photos per Ref	Ś	Ś	Ś	10%
Ext photos per refraction	Ś	Ś	Ś	10%

WHAT IS THE REALITY IN TX/ALA/CA?



	Average	High	Low	GOAL	
992x3 vs. 992x4 Ratio	4.72	15.75	1.33	~ 1.00	
992xx per Refraction	31.14%	63.66%	7.75%	> 50%	
VF per Refraction	7.37%	20.26%	1.79%	10%	
OCT-N per Refraction	8.69%	19.97%	3.94%	10%	
Gonio per Refraction	3.05%	16.64%	0	10%	
OCT-M per Refraction	8.24%	19.25%	1.87%	10%	
Fundus photos per Ref	34.19%	99.46% (optos?)	1.67%	10%	
Ext photos per refraction	1.00%	3.95%	0	10%	

WHAT DO MY NUMBERS LOOK LIKE?



	Average	Suburbs	Small Town	GOAL
992x3 vs. 992x4 Ratio	1.17	1.54	0.80	~ 1.00
	,		0.00	
992xx per Refraction	42.5%	25%	60%	> 50%
VF per Refraction	10%	5%	15%	10%
OCT-N per Refraction	19.5%	7%	32%	10%
Gonio per Refraction	5%	3%	7%	10%
OCT-M per Refraction	12.5%	8%	17%	10%
Fundus photos per Ref	6.5%	5%	8%	10%
Ext photos per refraction	9%	10%	8%	10%




HOW DO WE CHANGE?

KEY INSIGHT

• Beliefs underlie actions

Actions reinforce beliefs







Beliefs/Identity


BEHAVIORAL CHANGE REQUIRES BOTH



Actions



©GLE Consulting







INCREASE MEDICAL CARE IN COMPREHENSIVE EYE CARE IN 7 STEPS




STEP 1	Know Your Numbers
STEP 2	Utilize 99 Codes Appropriately
STEP 3	Implement/Improve Glaucoma Protocol
STEP 4	Implement/Improve Macular Disease Protocols
STEP 5	Implement/Improve DM and Peripheral Disease Protocols
STEP 6	Implement/Improve Ocular Surface Disease Protocols
STEP 7	Make Managed Vision Care Optional With Total Patient Care

General Payments by Nature of Payment in 2022 What are the different natures of payment?

Nature of payment \$	Amount (%) 🗢	Number of Payments \$
 Food and Beverage 	\$138.54 (100.0%)	3

Top Companies Making General Payments in 2022







List of General Payments in 2022







Welcome to Optometry Simplified.

In this biweekly blog post, I've curated the best resources to help you grow personally and professionally.


My mission is to find what's best for my patients and my practice.

Here's what I've found...





- Online Community
- Access to B&C and many more courses
- Mastermind Groups
- Monthly "Office Hours"
- Disease centric metrics



INCREASE MEDICAL CARE IN COMPREHENSIVE EYE CARE IN 7 STEPS



STEP 1	Know Your Numbers
STEP 2	Utilize 99 Codes Appropriately
STEP 3	Implement/Improve Glaucoma Protocol
STEP 4	Implement/Improve Macular Disease Protocols
STEP 5	Implement/Improve DM and Peripheral Disease Protocols
STEP 6	Implement/Improve Ocular Surface Disease Protocols
STEP 7	Make Managed Vision Care Optional With Total Patient Care

Know Your Numbers

9 KPI's to Grow Medical Optometry

- Revenue per OD Hour
- 992x3 vs 992x4
- 992xx per Refraction
- VF per Refraction
- OCT-N per Refraction
- Gonioscopy per Refraction
- OCT-M per Refraction
- Fundus Photos per Refraction
- External Photos per Refraction


STEP 1 Know Your Numbers

9 KPI's to Grow Medical Optometry

<u>Revenue per OD Hour</u>

- 992x3 vs 992x4
- 992xx per Refraction
- VF per Refraction
- OCT-N per Refraction
- Gonioscopy per Refraction
- OCT-M per Refraction
- Fundus Photos per Refraction
- External Photos per Refraction

Gross Revenue per OD Hour by Practice Size



- Revenue per OD Hour
- <u>992x3 vs 992x4</u>
- 992xx per Refraction
- VF per Refraction
- OCT-N per Refraction
- Gonioscopy per Refraction
- OCT-M per Refraction
- Fundus Photos per Refraction
- External Photos per Refraction

GOAL = RATIO ~ 1

- Revenue per OD Hour
- 992x3 vs 992x4
- <u>992xx per Refraction</u>
- VF per Refraction
- OCT-N per Refraction
- Gonioscopy per Refraction
- OCT-M per Refraction
- Fundus Photos per Refraction
- External Photos per Refraction

Know Your Numbers STEP 1

9 KPI's to Grow Medical Optometry

- Revenue per OD Hour
- 992x3 vs 992x4
- 992xx per Refraction
- VF per Refraction
- OCT-N per Refraction
- Gonioscopy per Refraction
- OCT-M per Refraction
- Fundus Photos per Refraction
- **External Photos per Refraction**

Cureus

Open Access Review

Article

DOI: 10.7759/cureus.11686

Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future

Karen Allison¹, Deepkumar Patel², Omobolanle Alabi³

1. Ophthalmology, Mount Sinai Hospital, New York, USA 2. Public Health, New York Medical College, School of Health Science and Practice, Valhalla, USA 3, Public Health, New York Medical College, Valhalla, USA

Corresponding author: Deepkumar Patel, deepkumarptl@gmail.com

Abstract

Glaucoma is a multifactorial optic degenerative neuropathy characterized by the loss of retinal ganglion cells. It is a combination of vascular, genetic, anatomical, and immune factors. Glaucoma poses a significant public health concern as it is the second leading cause of blindness after cataracts, and this blindness is usually irreversible. It is estimated that 57.5 million people worldwide are affected by primary open-angle glaucoma (POAG). People over 60 years of age, family members of those already diagnosed with glaucoma, steroid users, diabetics, as well as those with high myopia, hypertension, central cornea thickness of <5 mm and eye injury are at an increased risk of glaucoma. By 2020, it is expected that approximately 76 million people will suffer from glaucoma with that number estimated to reach 111.8 million by 2040.

In this article, we perform an extensive literature review focusing on the epidemiology of glaucoma and try to determine the number of people affected; we categorize them by sex, location, and level of income. Furthermore, we strive to estimate the future projection of the disease in the next 20 years (2040) while determining the disease burden, including the cost involved in treating and preventing the disease and the disease and disability projection of glaucoma.

- Revenue per OD Hour
- 992x3 vs 992x4
- 992xx per Refraction
- VF per Refraction
- OCT-N per Refraction
- Gonioscopy per Refraction
- OCT-M per Refraction
- Fundus Photos per Refraction
- External Photos per Refraction

STEP 1 Know Your Numbers

9 KPI's to Grow Medical Optometry

- Revenue per OD Hour
- 992x3 vs 992x4
- 992xx per Refraction
- VF per Refraction
- OCT-N per Refraction
- Gonioscopy per Refraction
- OCT-M per Refraction
- Fundus Photos per Refraction
- External Photos per Refraction

EVIDENCE-BASED CLINICAL PRACTICE GUIDELINE

Care of the Patient with Primary Open-Angle Glaucoma

18 Oct 2023

AMERICAN OPTOMETRIC ASSOCIATION

POAG Draft Two

13

14

- Revenue per OD Hour
- 992x3 vs 992x4
- 992xx per Refraction
- VF per Refraction
- OCT-N per Refraction
- Gonioscopy per Refraction
- OCT-M per Refraction
- Fundus Photos per Refraction
- External Photos per Refraction

STEP 1 Know Your Numbers

9 KPI's to Grow Medical Optometry

- Revenue per OD Hour
- 992x3 vs 992x4
- 992xx per Refraction
- VF per Refraction
- OCT-N per Refraction
- Gonioscopy per Refraction
- OCT-M per Refraction
- Fundus Photos per Refraction
- External Photos per Refraction

	ican J ithalm								AAO Member Access	Submit	Log in
Articles		Topics	Multimedia	CME	About	Contact					Search
	Patterna Glaucou Lee Jun Hui Show all au	s and [ma Eva i * • Yoo Kr ithors • Sh	aluations	s in Re in the ^{hristina} •	United	d States ian • Sanvice	ente Carina •)uring Initi Xu Benjamin א		Purchase	Subscribe :
Article info Related Articles	DESIC Retrosp METH Patients	ess pattern GN bective, ca IODS s undergo	ase-control stu	udy. Icoma ev	valuation	between 20	009-2020 w		tates. n the Optum Clinformati		lart.

- Revenue per OD Hour
- 992x3 vs 992x4
- 992xx per Refraction
- VF per Refraction
- OCT-N per Refraction
- Gonioscopy per Refraction
- OCT-M per Refraction
- Fundus Photos per Refraction
- External Photos per Refraction

- Revenue per OD Hour
- 992x3 vs 992x4
- 992xx per Refraction
- VF per Refraction
- OCT-N per Refraction
- Gonioscopy per Refraction
- OCT-M per Refraction
- Fundus Photos per Refraction
- External Photos per Refraction

- Revenue per OD Hour
- 992x3 vs 992x4
- 992xx per Refraction
- VF per Refraction
- OCT-N per Refraction
- Gonioscopy per Refraction
- OCT-M per Refraction
- Fundus Photos per Refraction
- External Photos per Refraction

9 KPI's to Grow Medical Optometry

- Revenue per OD Hour
- 992x3 vs 992x4
- 992xx per Refraction
- VF per Refraction
- OCT-N per Refraction
- Gonioscopy per Refraction
- OCT-M per Refraction
- Fundus Photos per Refraction
- External Photos per Refraction

GOAL = 10%+

INCREASE MEDICAL CARE IN COMPREHENSIVE EYE CARE IN 7 STEPS



STEP 1	Know Your Numbers
STEP 2	Utilize 99 Codes Appropriately
STEP 3	Implement/Improve Glaucoma Protocol
STEP 4	Implement/Improve Macular Disease Protocols
STEP 5	Implement/Improve DM and Peripheral Disease Protocols
STEP 6	Implement/Improve Ocular Surface Disease Protocols
STEP 7	Make Managed Vision Care Optional With Total Patient Care

Utilize 99 Codes Appropriately

	Problems	Data	Risk	Time
99202 99212	<u>Minimal</u> •1 Self-limited or minor problem	<u>Minimal</u> •Minimal (< 2) or no orders, tests performed, or additional documents analyzed	<u>Minimal</u> Minimal risk of morbidity from additional diagnostic testing or treatment	NP:15-29 mins EP: 10-19 mins
99203 99213	<u>Low</u> •2 or more self-limited or minor problems; or •1 stable chronic illness; or •1 acute, uncomplicated illness or injury	Limited •2 orders, tests performed, or additional documents analyzed, or •assessment requiring an independent historian	<u>Low</u> Low risk of morbidity from additional diagnostic testing or treatment. Example: •OTC medication	NP: 30-45 mins EP: 20-29 mins
99204 99214	Moderate •1 or more chronic illnesses with exacerbation, progression, or side effects of treatment; or •2 or more stable chronic illnesses; or •1 undiagnosed new problem with uncertain prognosis; or •1 acute illness with systemic symptoms; or •1 acute complicated injury	<u>Moderate</u> Any 1 of the following: •3 orders, tests performed, or additional documents analyzed •Independent interpretation of a test performed by another physician •Discussion of management or test interpretation with external physician	Moderate Moderate risk of morbidity from additional diagnostic testing or treatment. Examples: •Prescription drug medication •Decision regarding minor surgery with identified patient or procedure risk factors •Decision regarding major surgery without identified patient or procedure risk factors •Diagnosis or treatment significantly limited by social determinants of health	NP: 45-59 mins EP: 30-39 mins
	 High I or more chronic illnesses with severe 	<u>Extensive</u> Any 2 of the following:	<u>High</u> High risk of morbidity from additional diagnostic testing or	NP: 60-74 mins EP: 40-54 mins

•1 or more chronic illnesses with severe exacerbation, progression, or side effects of treatment; or

•1 acute or chronic illness or injury that

O O O O E


Any 2 of the following:

•3 orders, tests performed, or additional documents analyzed Independent interpretation of a test performed High risk of morbidity from additional diagnostic testing or treatment. Examples:

•Drug therapy requiring intensive monitoring for toxicity •Decision for elective major surgery with identified patient or

	Problems	Data	Risk	Time
99202 99212	<u>Minimal</u> •1 Self-limited or minor problem	<u>Minimal</u> •Minimal (< 2) or no orders, tests performed, or additional documents analyzed	<u>Minimal</u> Minimal risk of morbidity from additional diagnostic testing or treatment	NP:15-29 mins EP: 10-19 mins
99203 99213	<u>Low</u> •2 or more self-limited or minor problems; or •1 stable chronic illness; or •1 acute, uncomplicated illness or injury	<u>Limited</u> •2 orders, tests performed, or additional documents analyzed, or •assessment requiring an independent historian	Low Low risk of morbidity from additional diagnostic testing or treatment. Example: •OTC medication	NP: 30-45 mins EP: 20-29 mins
99204 99214	Moderate •1 or more chronic illnesses with exacerbation, promotion r sick of treatment; or •2 or more stable chrone illness; or •1 undiagnosed new problem uncert prognosis; or •1 acute illness with systemic symptoms; or •1 acute complicated injury	Moderate Any 1 of the following: •3 states, to the effort of a didition dominants of the effort of a dist part of the part of the erportion of a dist part of business of the agence of est intermetation with external physician	Moderate Moderate risk of morbidity from additional diagnostic testing the testing testing the testing testin	NP: 45-59 mins EP: 30-39 mins
99205 99215	High •1 or more chronic illnesses with severe exacerbation, progression, or side effects of treatment; or •1 acute or chronic illness or injury that poses a threat to life or bodily function	Extensive Any 2 of the following: •3 orders, tests performed, or additional documents analyzed •Independent interpretation of a test performed by another physician •Discussion of management or test interpretation with external physician	HighHigh risk of morbidity from additional diagnostic testing ortreatment. Examples:•Drug therapy requiring intensive monitoring for toxicity•Decision for elective major surgery with identified patient orprocedure risk factors•Decision for emergency major surgery•Decision regarding hospitalization•Decision not to resuscitate or to deescalate care because of	NP: 60-74 mins EP: 40-54 mins

poor prognosis



Implement/Improve Glaucoma Protocol




STEP 3

Implement/Improve Glaucoma Protocol

STEP 3



Implement/Improve Glaucoma Protocol



Implement/Improve Glaucoma Protocol

Annual Routine Exam

- A. Case history
- B. Health status of the visual system evaluation This must include:
 - 1. External and internal examination to include direct and/or indirect ophthalmoscopy
 - 2. Neurological integrity pupillary reflexes and extraocular muscle assessment (versions)
 - 3. Biomicroscopy
 - 4. Gross visual fields
 - 5. Tonometry
- C. Refractive status evaluation
 - This must include:
 - Visual acuity entering visual acuity with habitual Rx or unaided acuity (as indicated) and best corrected acuity
 - 2. Subjective refraction and accommodative function
 - 3. At least one of the following two optional tests:
 - a. objective refraction by retinoscopy or autorefractor
 - b. keratometry

- D. Binocular function
 - This must include recorded data from at least one of the following:
 - 1. Cover testing
- 2. NPC

- 4. Stereopsis
- 5.


3. Phorias

- 5. Vergence testing
- 6. Grade of fusion

- 7. Fixation disparity
- 8. Prism reflex test
- 9. Hirschberg corneal reflexes

E. Diagnosis/treatment plan (Use of ICD-10-CM diagnosis code is suggested.)

Implement/Improve Glaucoma Protocol



Implement/Improve Glaucoma Protocol

Elevated IOP

Myopia

Thinner central corneal thickness

Older age

African race or Latino/Hispanic ethnicity

Lower systolic and diastolic blood pressure

Disc hemorrhage

Larger cup-to-disc ratio

Family history


Type 2 diabetes mellitus

Visual field loss

RISK FACTORS

Low Risk: < 3High Risk: ≥ 3


Implement/Improve Glaucoma Protocol





Glaucoma Prevalence:

- 2.4% to 4.0% over
 40 (all races)
 - 5.2% over 60 (AA)

lacksquare







1: Visual fields may need to be repeated up to 3-5 times in first 2 years of diagnosis to find progression.

2: Recommended re-evaluation interval until stability established.


3: Gonioscopy is recommended yearly or as conditions indicate.

4: ONH imaging, especially OCT may not be reliable for severe glaucoma damage due to floor effect.


INCREASE MEDICAL CARE IN COMPREHENSIVE EYE CARE IN 7 STEPS



STEP 1	Know Your Numbers
STEP 2	Utilize 99 Codes Appropriately
STEP 3	Implement/Improve Glaucoma Protocol
STEP 4	Implement/Improve Macular Disease Protocols
STEP 5	Implement/Improve DM and Peripheral Disease Protocols
STEP 6	Implement/Improve Ocular Surface Disease Protocols
STEP 7	Make Managed Vision Care Optional With Total Patient Care



Implement/Improve Macular Disease Protocols



AMD Prevalence:

•

•

•


- 7.1% over 40
- 12.5% over 60
 - 33.3% over 75

STEP 4 Implement/Improve Macular Disease Protocols <u>Care</u> Early/Mild Based upon disease ٠ AMD stage AdaptDx q1yr Q6-12months OCT q3-12 months Annual FAF/Macular Intermediate/ Moderate photos, OCT, Routine AMD AdaptDx Q6 months Exam Ext, MPOD <u>Capture</u> RTO in 1-3 Advanced/ <u>Code</u> Triggers months Severe 92012 or 99213 • MPOD < 0.25 and > 92133 50 yrs old \bullet AMD Macular RPE changes 92284 Q3-6 months Macular drusen ٠ 92250


Implement/Improve Macular Disease Protocols

AMD Plan


Vis	it#	Subclinical	Category 1	Category 2	Category 3	Category 4 - Dry
	Potential	Comprehensive	Comprehensive	Comprehensive	Comprehensive	Comprehensive
		Examination,	Examination,	Examination,	Examination,	Examination,
	Services	Refraction. Mac	Refraction, Mac	Refraction, Mac	Refraction, Mac	Refraction, Mac
1	Services	OCT, retinal	OCT, retinal	OCT, retinal	OCT, retinal	OCT, retinal
		screener	screener	screener	screener	screener
	Potential	92014, 92015,	92014, 92015,	92014, 92015,	92014, 92015,	92014, 92015,
	Codes	92134, optos	92134, optos	92134, optos	92134, optos	92134, optos
	Potential		Office Visit,	Office Visit,	Office Visit,	Office Visit,
	Services	Dark Adaptation	Photos, DA	Photos, DA	Photos, DA, 10-2	
2						
	Potential	92284	99213, 92250,	99213, 92250,	99214, 92250,	99213, 92250,
	Codes	52204	92284	92284	92284, 92083	92083
3	Potential				Office Visit, Mac	
	Services				OCT A	
	Potential				99213, 92134	
	Codes				55215, 52154	



Implement/Improve Macular Disease Protocols



ERM Prevalence:
2.2% to 28.9%
VMT Prevalence:
0.4% to 2.0%



Implement/Improve Macular Disease Protocols

	ERM/MH Plan					
Visit #		VMA	VMT	ERM	Stage 1 MH	
1	Potential Services	Refraction, Mac	Comprehensive Examination, Refraction, Mac OCT, retinal screener	Comprehensive Examination, Refraction, Mac OCT, retinal screener	Comprehensive Examination, Refraction, Mac OCT, retinal screener	
	Potential Codes		92014, 92015, 92134, optos	92014, 92015, 92134, optos	92014, 92015, 92134, optos	
	Potential Services	,	Office Visit, Mac OCT	Office Visit, Mac OCT	Office Visit, Mac OCT, 10-2	
2	Potential Codes	99213.92134	99213, 92134	99213, 92134	99213, 92134, 92083	
3	Potential Services				Office Visit, Mac OCT	
5	Potential Codes				99213, 92134	
4	Potential Services				Office Visit, Mac OCT	
	Potential Codes				99213, 92134	

INCREASE MEDICAL CARE IN COMPREHENSIVE EYE CARE IN 7 STEPS



STEP 1	Know Your Numbers
STEP 2	Utilize 99 Codes Appropriately
STEP 3	Implement/Improve Glaucoma Protocol
STEP 4	Implement/Improve Macular Disease Protocols
STEP 5	Implement/Improve DM and Peripheral Disease Protocols
STEP 6	Implement/Improve Ocular Surface Disease Protocols
STEP 7	Make Managed Vision Care Optional With Total Patient Care

Implement/Improve DM and Peripheral Disease Protocols

eople don't

hey have it

Views 4,944 | Citations 9 | Altmetric 761 This Issue

Original Investigation

June 15, 2023



Prevalence of Diabetic Retinopathy in the US in 2021

Elizabeth A. Lundeen, PhD¹; Zeb Burke-Conte, BS²; David B. Rein, PhD, MPA³; et al

» Author Affiliations

JAMA Ophthalmol. 2023;141(8):747-754. doi:10.1001/jamaophthalmol.2023.2289

Editorial Comment


Key Points

Question What was the 2021 US prevalence of diabetic retinopathy and vision-threatening diabetic retinopathy?

Findings The study ceam estimated that 9.60 million people in the US (26.43% of those with diabetes) ad diabetic retinopathy and 1.84 million people (5.06% of those with diabetes) had vision-threatening diabeted retinopathy in 2021. There was marked variation in prevalence across states and the number of people living with diabetes-related eye disease grew substantially since provalence was last estimated in 2004.

Meaning The US prevalence of diabetes-related eye disease remains high and may grow in the coming decades


Implement/Improve DM and Peripheral Disease Protocols



STEP 5



Implement/Improve DM and Peripheral Disease Protocols



Implement/Improve DM and Peripheral Disease Protocols



Prevalence **Posterior Vitreous Detachment:** • 24% of 50-59 yo • 87% of 80-89 yo Lattice Degeneration: 6-8% Atrophic holes: 5% **Choroidal Nevus: 5%**

Implement/Improve DM and Peripheral Disease Protocols



STEP 5

Protecting Sight. Empowering Lives.®

Posterior Vitreous Detachment, Retinal Breaks, and Lattice Degeneration Preferred Practice Pattern®


Asymptomatic operculated holes Asymptomatic atrophic round holes Asymptomatic lattice degeneration without holes Asymptomatic lattice degeneration with holes Asymptomatic dialyses Eyes with atrophic holes, lattice degeneration, or asymptomatic PVD, Retinal Breaks, and Lattice Degeneration PPP

TABLE 3 RECOMMENDED GUIDELINES FOR FOLLOW-UP

Type of Lesion	Follow-up Interval		
Symptomatic PVD with no retinal break	Depending on symptoms, risk factors, and clinical findings, patients may be followed within 2 months, then 6-12 months		
Symptomatic PVD with no retinal break but with some vitreous or retinal hemorrhage	Depending on the severity of the retinal hemorrhage, 1-2 weeks		
	For vitreous hemorrhage, weekly until resolved. Ultrasonography to check for retinal tears		
Acute symptomatic horseshoe tears	1–2 weeks after treatment, then 4–6 weeks, then 3–6 months, then annually		
Acute symptomatic operculated holes	2-4 weeks, then 1-3 months, then 6-12 months, then annually		
Acute symptomatic dialyses	1–2 weeks after treatment, then 4–6 weeks, then 3–6 months, then annually		
Traumatic retinal breaks	1–2 weeks after treatment, then 4–6 weeks, then 3–6 months, then annually		
Asymptomatic horseshoe tears	1–4 weeks, then 2–4 months, then 6–12 months, then annually		
Asymptomatic operculated holes	1-4 months, then 6-12 months, then annually		
Asymptomatic atrophic round holes	1-2 years		
Asymptomatic lattice degeneration without holes	Annually		
Asymptomatic lattice degeneration with holes	Annually		
Asymptomatic dialyses	 If untreated, 1–4 weeks, then 3 months, then 6 months, then every 6 months 		
	 If treated, 1–2 weeks after treatment, then 4–6 weeks, then 3–6 months, then annually 		
Eyes with atrophic holes, lattice degeneration, or asymptomatic horseshoe tears in patients who have had a retinal detachment in the fellow eye	Every 6-12 months		

PVD = posterior vitreous detachment

© 2019 by the American Academy of Ophthalmology Published by Elsevier Inc. http://dx.doi.org/10.1016/j.ophtha.2019.09.027 ISSN 0161-6420/19




INCREASE MEDICAL CARE IN COMPREHENSIVE EYE CARE IN 7 STEPS




STEP 1	Know Your Numbers
STEP 2	Utilize 99 Codes Appropriately
STEP 3	Implement/Improve Glaucoma Protocol
STEP 4	Implement/Improve Macular Disease Protocols
STEP 5	Implement/Improve DM and Peripheral Disease Protocols
STEP 6	Implement/Improve Ocular Surface Disease Protocols
STEP 7	Make Managed Vision Care Optional With Total Patient Care

Implement/Improve Ocular Surface Disease Protocols



Implement/Improve Ocular Surface Disease Protocols


DRY EYE/OCULAR SURFACE DISEASE



Prevalence DED signs and symptoms: • 8.7 to 30.1% MGD: 38-68%

Implement/Improve Ocular Surface Disease Protocols

STEP 6



STEP 6 Implement/Improve Ocular Surface Disease Protocols

Signs \ Tx	At Home/OTC	In Office	Pharm/Rx
< Tear Meniscus < Schirmer Score	PF ATs	Punctal occlusion: 180 days, permanent, or cauterization	Cyclosporin, varenicline, amniotic membrane, autologous serum tears, scleral lens
Lid telangiectasia (+)Inflammadry	Omega 3s	Intense Pulsed Light	Doxy/minocycline, amniotic membrane, autologous serum tears, scleral lens
MGSS < 10 MG atrophy	Warm compresses PF ATs	Thermal pulsation, MG expression, lid debridement, LLLT w/ expression, RF w/ expression	Amniotic membrane, autologous serum tears, scleral lens
(+)collarettes (+)scurf (+)madarosis	Lid hygiene: gel, spray, or wipes, Nulids TM	Blephex [™] , etc.	Lotilaner 0.25%

INCREASE MEDICAL CARE IN COMPREHENSIVE EYE CARE IN 7 STEPS



STEP 1	Know Your Numbers
STEP 2	Utilize 99 Codes Appropriately
STEP 3	Implement/Improve Glaucoma Protocol
STEP 4	Implement/Improve Macular Disease Protocols
STEP 5	Implement/Improve DM and Peripheral Disease Protocols
STEP 6	Implement/Improve Ocular Surface Disease Protocols
STEP 7	Make Managed Vision Care Optional With Total Patient Care

Make Managed Vision Care Optional With Total Patient Care



STEP 7


Make Managed Vision Care Optional With Total Patient Care



992xx per Refraction GOAL = 50%+

ONE LAST THING WE MISSED...








Further Customized Help

- Online Community
- Access to B&C and many more courses
- Mastermind Groups
- Monthly "Office Hours"
- Disease centric metrics



AUTO Calculate YOUR Medical KPIs

FREE WHITEPAPER

9 Key Metrics for Medical Optometry Success

Empower Your Optometric Practice with Valuable Insights and Key Performance Indicators related to Comprehensive Optometry





QUESTIONS ?